Health Canada has authorised the country's first generic version of semaglutide for weight loss, marking the third generic semaglutide product cleared by the regulator this year. According to reports from Health Canada, the approved product, branded Svemia, was submitted by Canadian pharmaceutical firm Apotex as a generic equivalent of Wegovy, the brand-name weight-loss injection. The injection is approved for once-weekly use in patients aged 12 and above, to be used alongside a reduced-calorie diet and increased physical activity for chronic weight management. This approval comes as part of a broader trend toward increasing accessibility to GLP-1 receptor agonists, with the distinction being crucial as earlier generics were for diabetes management while Svemia is specifically cleared for weight loss.
Health Canada said the authorisation followed a thorough review in which Apotex demonstrated the drug met the regulator's safety, efficacy and quality standards for generics. As reported by Health Canada, the department noted that generic semaglutide products are pharmaceutically equivalent to the original biologic drug, with its review process ensuring differences between the two do not affect safety, efficacy or quality. The approval suggests that the Canadian regulatory body has validated Apotex's manufacturing process and the stability of the injection formulation, though it's important to note that while the active ingredient is the same, the inactive ingredients may differ slightly. These differences are strictly regulated to ensure they do not impact the efficacy or safety of the treatment. Health Canada added that it would continue monitoring the safety and effectiveness of all generic semaglutide products following approval and would act if any unexpected concerns emerged.
Health Canada said it is currently reviewing six other submissions for generic semaglutide from different companies and expects to issue further regulatory decisions in the coming weeks and months. According to reports from Health Canada, the latest clearance follows two earlier milestones for Apotex. On April 28, Health Canada became the first regulator among G7 nations to approve a generic version of semaglutide, followed by a separate approval on May 1 for once-weekly treatment of adult type 2 diabetes patients to manage blood sugar levels. The pipeline suggests a future with increased competition and potentially greater supply stability, as when multiple manufacturers produce the same medication, the risk of shortages decreases significantly.
Health Canada noted that generic medications in Canada are typically priced 45 to 90% lower than their brand-name counterparts, raising the prospect of significant cost savings for patients and the wider healthcare system as more generics enter the market. As reported by Health Canada, semaglutide-based drugs, including Novo Nordisk's Ozempic and Wegovy, have seen explosive global demand in recent years for both diabetes management and weight loss, prompting regulators worldwide to fast-track generic alternatives. The key distinction lies in the manufacturer and cost structure, with Apotex producing Svemia while Novo Nordisk produces the original Wegovy, historically making generics available after patent expiration. For patients, the primary benefit is the potential for reduced cost, which could make long-term weight management more sustainable.
